147 related articles for article (PubMed ID: 16280758)
1. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression.
Osman I; Mikhail M; Shuch B; Clute M; Cheli CD; Ghani F; Thiel RP; Taneja SS
J Urol; 2005 Dec; 174(6):2174-7. PubMed ID: 16280758
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
3. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T
Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
5. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
[TBL] [Abstract][Full Text] [Related]
6. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential.
Ricciardelli C; Jackson MW; Choong CS; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
Prostate; 2008 Jun; 68(8):830-8. PubMed ID: 18324648
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
[TBL] [Abstract][Full Text] [Related]
9. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
[TBL] [Abstract][Full Text] [Related]
10. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
Woll MM; Hueman MT; Ryan GB; Ioannides CG; Henderson CG; Sesterhan IA; Shrivasta S; McLeod DG; Moul JW; Peoples GE
Int J Oncol; 2004 Dec; 25(6):1769-80. PubMed ID: 15547716
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer.
Zhang YF; Guan YB; Yang B; Wu HY; Dai YT; Zhang SJ; Wang JP; Anoopkumar-Dukie S; Davey AK; Sun ZY
Chin Med J (Engl); 2011 Dec; 124(24):4345-9. PubMed ID: 22340411
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
Kundu SD; Roehl KA; Yu X; Antenor JA; Suarez BK; Catalona WJ
J Urol; 2007 Feb; 177(2):505-9. PubMed ID: 17222621
[TBL] [Abstract][Full Text] [Related]
13. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
[TBL] [Abstract][Full Text] [Related]
18. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer.
Kuerer HM; Thompson PA; Krishnamurthy S; Fritsche HA; Marcy SM; Babiera GV; Singletary SE; Cristofanilli M; Sneige N; Hunt KK
Clin Cancer Res; 2003 Feb; 9(2):601-5. PubMed ID: 12576424
[TBL] [Abstract][Full Text] [Related]
19. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
20. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients.
Hoopmann M; Sachse K; Valter MM; Becker M; Neumann R; Ortmann M; Göhring UJ; Thomas A; Mallmann P; Schöndorf T
Eur J Cancer Care (Engl); 2010 Nov; 19(6):809-15. PubMed ID: 20105224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]